First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting

By sjmartinez • September 29, 2024

Nicholas SB, Correa-Rotter R, Desai NR, Guo L, Navaneethan SD, Pantalone KM, Wanner C, Hamacher S, Fatoba ST, Horvat-Broecker A, Garreta-Rufas A, Gay A, Merz M, Wheeler DC. First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting. J Nephrol. 2024 Sep 28. doi: 10.1007/s40620-024-02070-y. Epub ahead of print. PMID: 39340711.

Tags: Chronic kidney disease, Finerenone, Nephrology, Non-interventional study, Publications, Type 2 diabetes

Obesity and Cardio-Metabolic Health in Kidney Disease: Implications for Kidney Health, Risk Stratification, and Management

Mathew RO, Hong A, Narasaki Y, Fung E, Cheung D, Han J, Durstenfeld MS, Hsue PY, Rhee CM. Obesity and Cardio-Metabolic Health in Kidney Disease:[...]

Enhancing Evidence Generation by Linking Randomized Clinical Trials to Real-World Data: The INVESTED-Medicare Linkage Study

Cho H, Shin H, Najafzadeh M, Claggett B, Ortega-Montiel J, Liu J, Paik JM, Lalani NF, Bradley MC, Concato J, Solomon SD, Vardeny O, Patorno[...]

Comparative Short-term Risk of Severe Gastrointestinal Events Associated With Opioid Type Among Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

Bea S, Patorno E, Sreedhara SK, Wexler DJ, Cromer SJ, Glynn RJ, Paik JM, Bykov K. Comparative Short-term Risk of Severe Gastrointestinal Events Associated With[...]